Biosensors assigned ‘buy’ rating – OCBC
OCBC Investment Research said it has initiated coverage of Biosensors International Group with a “buy” call and a fair value of 1.05 sgd on the company’s positive outlook given the likelihood of regulatory approval for its BioMatrix drug-eluting stent (DES) and higher sales of its biodegradable DES technology. “We forecast that regulatory approval for Biosensors’ Biomatrix will come in the first quarter of next year. As such, we see a jump in DES sales to start in the year to March 2008,” OCBC said in a note.
For the year to March 2007 and 2008, OCBC forecasts DES sales at Biosensors to grow 101 pct and 388 pct year-on-year, respectively. The brokerage also noted that the positive clinical feedback for the company’s DES technology and its recent collaborative agreement with JW Medical Systems to market DES products in China bode well for Biosensors as it works towards a polymer-free DES and benefit from the lower manufacturing costs and JW Medical’s distribution networks in china.
February 14th, 2012 at 4:41 am
This approach always amazes me how affiliate marketers such as all by yourself can discover enough time in addition to the loyalty to stay regarding designing extraordinary writes. Your site issuperb and with excellent need to start reading confidential different blogs. I wanted to say thanks.
February 24th, 2012 at 10:30 pm
Piece of content and even to the time. I really don’t determine furthermore this is in truth the best shop to ask unfortunately do you ever mankind has any kind of thoughts on best places take on a certain amount of professional writers? Hi and thanks
April 30th, 2012 at 2:32 pm
I cling on to listening to the news broadcast lecture about receiving boundless online grant applications so I have been looking around for the finest site to get one. Could you advise me please, where could i find some?
May 7th, 2012 at 11:42 am
Very! Very! Very! impressed with your article. And as always¡very. very, very proud of you!